Ryan McQuaid Prosper Medical is a founder story with an unusual credibility marker most first-time healthtech founders can’t claim: a $450 million exit already behind them.
McQuaid is the co-founder and CEO of Prosper Medical, a San Francisco startup building an AI-powered concierge primary care platform, alongside Dr. James Wantuck, the same physician co-founder he built PlushCare with a decade earlier.
In July 2026, Prosper Medical closed a $16 million seed round led by FUSE, returning to a problem the pair thought they’d already solved once, only to conclude that convenience alone was never the real fix. Here is why two founders with a proven exit decided to build almost the same company again, differently.
Who Is Ryan McQuaid?
Ryan McQuaid is the co-founder and CEO of Prosper Medical, according to his LinkedIn profile. He earned a Bachelor of Science in business administration from the University of California, Berkeley’s Haas School of Business, later returning to Haas for an MBA. Before founding PlushCare, McQuaid led AT&T’s mHealth platform and helped incubate AT&T EverThere, giving him direct experience inside large-scale digital health products before ever starting his own company.
McQuaid has also described himself as a three-sport Division I college athlete at Berkeley, a background that gave him unusually early and frequent access to quality healthcare, an advantage he has said he came to recognize most people simply don’t have.
The Text Message That Led to PlushCare
PlushCare’s origin story traces back to a personal health crisis. McQuaid was dealing with chronic back and joint pain severe enough that he could barely stand some mornings, without a primary care doctor to turn to and little experience navigating the healthcare system on his own. He reached out to a friend, James Wantuck, a Stanford-trained physician, and the two diagnosed and treated the condition largely over text messages and FaceTime calls.
That experience became the founding premise of PlushCare: take the human, personalized quality of that informal exchange and make it available to everyone digitally, rather than treating it as a favor available only to people lucky enough to know a doctor personally.
Building and Selling PlushCare to Accolade
McQuaid and Wantuck founded PlushCare in 2015, building one of the country’s first direct-to-consumer telehealth platforms. Wantuck, who holds an MD from Vanderbilt and completed his internal medicine training at Stanford, served as chief medical officer while also holding faculty positions at Stanford and the VA Palo Alto Health Care System. The company grew to more than 400,000 patients served, more than $35 million in annual revenue, and roughly 150 employees before Accolade acquired it in April 2021 for a reported $450 million.
That exit gave McQuaid and Wantuck both financial security and a rare kind of credibility: proof they could build and scale a consumer healthcare company from an idea into a nine-figure acquisition, well before they ever pitched Prosper Medical to a single investor.
The Problem Prosper Medical Set Out to Solve
Despite PlushCare’s success, McQuaid and Wantuck came away from the experience with a more complicated lesson than they expected. “When we built PlushCare, we learned that making appointments easier wasn’t enough,” McQuaid has said. The real challenge, he has explained, was everything happening after a patient leaves a visit: following up on test results, finding the right specialist, collecting comprehensive health data, and catching problems before they become serious.
Wantuck has echoed that same realization from the clinical side. “We grew PlushCare to more than a million patient visits a year, and through those millions of interactions, we really learned that there were some problems with just providing access to a great doctor,” he told Fierce Healthcare. Convenience, in other words, solved access, but not the deeper problem of continuity, the lack of a lasting, trusted relationship between a patient and a physician who actually knows their history.
Building Prosper Medical: Care Concierge Orchestration
Prosper Medical’s platform combines dedicated Care Concierge Teams with real-time AI signal detection, designed to flag clinical risks early and intervene before problems become acute, rather than waiting for a patient to notice something is wrong and schedule an appointment. The company operates as an in-network provider across all 50 states, deliberately avoiding a cash-only subscription model that would limit access to wealthier patients.
Wantuck has been explicit that Prosper’s model is not designed to replace physicians with AI. “We’re not looking to use AI to make healthcare cheap and quick, or eliminate physicians and other healthcare workers from the workflow,” he told Fierce Healthcare, a positioning that distinguishes Prosper from AI healthcare startups pitching automation primarily as a cost-cutting tool rather than a way to deepen physician-patient relationships.
Inside Prosper Medical’s $16 Million Seed Round
Ryan McQuaid Prosper Medical announced a $16 million seed round on July 23, 2026, led by FUSE, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures, and Western Technology Investment. The company says it will use the capital to expand its physician network, continue building out its AI platform, and accelerate growth into new markets.
That investor list, seven participating firms alongside a lead, reflects meaningful institutional interest in a healthtech round led by founders with an already-proven exit, a combination that likely reduced the diligence burden typical first-time healthcare founders face when raising early-stage capital.
Prosper Medical’s Position in the AI Healthcare Race
Prosper Medical enters an AI healthcare funding environment where investors are increasingly favoring startups attached to disciplined operational experience rather than pure model enthusiasm, according to reporting from Tech Startups. The company’s emphasis on physician relationships and in-network accessibility, rather than a purely cash-pay concierge model, positions Prosper differently from luxury-tier concierge medicine services that remain financially out of reach for most patients.
That distinction matters more in 2026 than it might have a few years earlier. Cash-pay concierge medicine has grown steadily in the U.S., but it remains a service available primarily to patients who can afford annual membership fees on top of standard insurance costs. By staying in-network across all 50 states, Prosper Medical is deliberately betting that AI-driven care coordination can deliver a similar depth of relationship without requiring patients to opt out of their existing insurance coverage, a harder operational path but a substantially larger addressable market.
That accessibility-first positioning is a direct extension of the lesson McQuaid and Wantuck say they took from PlushCare: technology should expand who can access high-quality, relationship-based care, not just make it more convenient for people who could already afford it.
What’s Next for Prosper Medical
With fresh seed capital in hand, Prosper Medical’s near-term priorities center on expanding its physician network and scaling its AI-driven care coordination platform across new U.S. markets. The company’s in-network insurance model gives it a broader potential patient base from the outset than a cash-pay-only competitor would have, though it also means navigating the operational complexity of working within traditional insurance systems at scale.
McQuaid and Wantuck’s return to primary care, rather than moving into an entirely different healthcare category after their PlushCare exit, suggests a level of conviction that the deeper problem they identified, continuity of care rather than access alone, remains large enough to justify building a second company around solving it.
Lessons for Entrepreneurs From Ryan McQuaid’s Journey
McQuaid’s path offers a clear lesson for founders returning to a market after a successful exit: the most credible second act often isn’t an entirely new idea, but a sharper, more specific version of the same problem, informed by lessons the first company’s own scale revealed. Second, Wantuck’s explicit positioning against using AI to eliminate physicians, rather than embracing full automation, suggests that founders returning to build in the same space can differentiate through philosophy and values as much as through new technology alone.
Third, Prosper Medical’s decision to remain in-network with traditional insurance, rather than pursuing a simpler cash-pay concierge model, reflects a willingness to take on more operational complexity in service of a larger total addressable market, a trade-off easier to justify with an already-proven founding team.
Frequently Asked Questions
Who is Ryan McQuaid? Ryan McQuaid is the co-founder and CEO of Prosper Medical. He previously co-founded PlushCare, one of the first direct-to-consumer telehealth platforms, which Accolade acquired in 2021 for a reported $450 million.
What does Prosper Medical do? Prosper Medical is an AI-powered concierge primary care platform that combines dedicated care teams with real-time AI signal detection to flag clinical risks early, aiming to build lasting physician-patient relationships rather than one-off appointments.
How much funding has Prosper Medical raised? Prosper Medical raised $16 million in seed funding, announced July 23, 2026, led by FUSE, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures, and Western Technology Investment.
Who co-founded Prosper Medical with Ryan McQuaid? Prosper Medical was co-founded by Ryan McQuaid and Dr. James Wantuck, who serves as chief medical officer. The two previously co-founded PlushCare together in 2015.
What happened to PlushCare? PlushCare, co-founded by McQuaid and Wantuck in 2015, grew to more than 400,000 patients and $35 million in annual revenue before Accolade acquired it in April 2021 for a reported $450 million.
Does Prosper Medical accept insurance? Yes. Prosper Medical operates as an in-network provider across all 50 states and works with many major insurance plans, rather than requiring a cash-only subscription.
Conclusion
Ryan McQuaid Prosper Medical is a reminder that even founders with a nine-figure exit already behind them sometimes conclude their first company only solved half the problem. With $16 million in fresh seed funding, a founding team with direct, proven experience scaling a healthcare startup to acquisition, and a more specific thesis around continuity of care rather than convenience alone, Prosper Medical is testing whether the lesson McQuaid and Wantuck took from PlushCare translates into an even larger outcome the second time around.
For more founder stories in healthcare and repeat entrepreneurship, see Lava Sunder’s Corner Health, Ed Bellis’s Empirical Security, and Jenny Duan’s Clair Health on Denote Press.
